Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860588 | 1.00 | PRKCI (0.33) | PRKCIALDH1A1KDM4EGLAGAA | |
| SCHEMBL20076621 | 0.84 | PRKCI (0.34) | PRKCIALDH1A1KDM4EGLAGAA | |
| SCHEMBL27298134 | 0.78 | CA1 (0.33) | PRKCI | |
| SCHEMBL30620243 | 0.78 | CA1 (0.33) | PRKCI | |
| SCHEMBL7995306 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4ENPC1POLBHTT | |
| SCHEMBL111957 | 0.77 | CES2 (0.36) | ALDH1A1BACE1 | |
| SCHEMBL25469250 | 0.76 | PRKCI (0.32) | PRKCIALDH1A1KDM4EGLAGAA | |
| SCHEMBL5513296 | 0.74 | MAP2K1 (0.33) | ALDH1A1KMT2A | |
| SCHEMBL1861299 | 0.73 | HDAC1 (0.45) | ALDH1A1KDM4EGAANPC1POLB | |
| SCHEMBL932096 | 0.73 | FEN1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119486992-A | PI3K alpha inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240150287-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | HANGZHOU APELOA MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| WO-2024029489-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MODULUS DISCOVERY, INC. (JP) | 2024-02-08 | — | — | WO | disclosed |
| EP-4282865-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| EP-4282865-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| EP-2448932-B1 | NOVEL 6-MORPHOLIN-4-YL-PYRIMIDIN-4-(3H)-ONE DERIVATIVES, AND THE PHARMACEUTICAL PREPARATION THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-03-05 | — | — | EP | disclosed |
| US-8507483-B2 | 1H-pyrimidin-2-one derivatives, preparation thereof and pharmaceutical use thereof as inhibitors of AKT (PKB) phosphorylation | SANOFI (FR) | 2013-08-13 | — | — | US | disclosed |
| EP-2448932-A1 | NOVEL 6-MORPHOLIN-4-YL-PYRIMIDIN-4-(3H)-ONE DERIVATIVES, AND THE PHARMACEUTICAL PREPARATION THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001115-A1 | NOVEL 6-MORPHOLIN-4-YL-PYRIMIDIN-4-(3H)-ONE DERIVATIVES, AND THE PHARMACEUTICAL PREPARATION THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150287-A1 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | ITGB7, ITGB4, ITGA4 | PRKCI 4003/4885ALDH1A1 988/4885KDM4E 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.